Dorsal root ganglion stimulation may help selected patients with focal nerve-related, CRPS-related, foot, groin, pelvic, or complex pain when other treatments have not provided enough relief.
For severe nerve pain that hasn't responded to other treatments, dorsal root ganglion (DRG) stimulation may offer targeted relief. Dr. Siefferman explains how DRG stimulation works, who may benefit from it, and how a temporary trial helps determine whether it's the right treatment.
Our team organizes conditions and treatments into related zones of expertise to make it easier to explore the care paths most relevant to your symptoms and goals.
Use the zone tags above to browse dedicated pages for each focus area, including services, providers, and what to expect during treatment.
Hi, I’m Dr. Jason Siefferman, an interventional pain specialist and medical director at Manhattan Pain Medicine. The dorsal root ganglion is the sensory hub. All of the sensory nerves in the arms and the legs and even around the thorax and abdomen come to enter the spine, and then there’s a cell body where all of those cells live, and that’s the dorsal root ganglion. Now, the dorsal root ganglion is a first step of sensitization for somatic nerves. This is separate from the sympathetic sensitization that occurs with sympathetic nerves or with chronic nerve injury in the somatic nerves, which leads to sympathetic sensitization.
Sensitization of the dorsal root ganglion is important to identify because it’s often responsible for chronic pain. We can prove its role by doing a diagnostic selective nerve root block. This is similar to an epidural without reaching the epidural space, just blocking the DRG. If that gives us a positive response, sometimes just that block by itself is therapeutic because it reboots that DRG a little bit. If not, then we can talk about DRG stimulation. Now, DRG stimulation is where we use an electrode in the spine exiting along the nerve root, which blocks pain from that nerve root. It uses electricity to disrupt the pain signaling. Now, it doesn’t stop normal sensation, but it’s programmed to stop pain sensation.
Now, does this work 100% for everyone all the time? Unfortunately, not. We do a trial first to see if it works for the patient. I place these leads under X-ray guidance. They stay in for a week. The patient works with the programmer to make sure they can work to test them out to see what utility they get from it during that week. And then at the end of the week, we pull the leads out and we then have a conversation of how much value did this provide. Generally, we need 80% or more relief to justify implanting a medical device.
But for patients who have complex regional pain syndrome, severe neuropathic pain, pelvic pain—for a lot of conditions which have just resisted every other available treatment modality, this is a consideration. Of course, this is only one mode of spinal cord stimulation. And technically, dorsal root ganglion, while it’s not stimulating the spinal cord, is still considered spinal cord stimulation. It’s in the same category. There’s also dorsal column stimulation, which we use along the spinal cord itself. That may also be something to have a discussion about, as well as peripheral nerve stimulation, which is outside the spine altogether.
These are all things that we use in our practice and, depending on what’s going on with the patient, we talk about what the most appropriate treatment is. This is generally used as a last resort. There’s a spectrum of treatments. We will work through all of these, and if this is something you are interested in, we are happy to talk about it in depth.
Dorsal root ganglion stimulation, often called DRG stimulation, is an advanced neuromodulation treatment that uses targeted electrical stimulation near the dorsal root ganglion, a cluster of sensory nerve cells near the spine involved in transmitting pain signals from specific body regions.
At Manhattan Pain Medicine, dorsal root ganglion stimulation NYC care begins with diagnosis-first evaluation. The goal is to determine whether pain is focal enough and anatomically appropriate for DRG stimulation, or whether another approach such as spinal cord stimulation, peripheral nerve stimulation, nerve blocks, spine injections, nerve hydrodissection, medication management, or surgery referral may be more appropriate. DRG stimulation is not a cure for chronic pain, and it is not appropriate for every patient. It is considered only after careful evaluation, safety screening, and a temporary trial before permanent implantation is discussed.
MPM specialists evaluate whether DRG stimulation may be appropriate by reviewing the patient’s pain location, nerve distribution, diagnosis, prior imaging, prior procedures, response to nerve blocks or sympathetic blocks, medication history, surgical history, pelvic pain overlap, spine findings, psychological readiness, functional goals, medical risks, and insurance requirements. DRG stimulation may be considered for selected patients with CRPS, focal neuropathic pain, foot pain, groin pain, pelvic nerve pain, pudendal neuralgia overlap, lower extremity nerve pain, sciatica, spine-related nerve pain, or complex chronic pain.
MPM also evaluates whether spinal cord stimulation, peripheral nerve stimulation, repeat injections, nerve hydrodissection, medication management, pain psychology, rehabilitation, or surgical referral may better fit the pain pattern.
Patients often search for dorsal root ganglion stimulation in Manhattan when pain is focal, severe, nerve-like, or difficult to treat. This may include lower extremity pain, foot pain, groin pain, pelvic pain, pudendal neuralgia overlap, CRPS, sciatica, pain after spine injury or surgery, or chronic pain that has not improved enough with medication, injections, physical therapy, pelvic floor therapy, or prior procedures.
MPM approaches DRG stimulation as a targeted neuromodulation option, not simply a stronger version of spinal cord stimulation. DRG stimulation may be especially relevant when pain follows a more specific regional or nerve-related distribution. The most important step is matching the treatment to the patient’s anatomy, pain pathway, prior response patterns, and goals. A temporary DRG stimulation trial is typically used before permanent implantation is considered.
Dorsal root ganglion stimulation fits within MPM’s Pelvic Pain, Complex Chronic Pain, Headache, and Musculoskeletal issues expertise because chronic pain often involves overlapping spine, nerve, pelvic, musculoskeletal, and nervous system pathways.
A patient may have CRPS, focal neuropathic pain, foot pain, groin pain, pelvic pain overlap, pudendal neuralgia overlap, sciatica, spine-related nerve pain, or central pain features. MPM evaluates how DRG stimulation fits within the broader care plan, which may also include spinal cord stimulation, peripheral nerve stimulation, peripheral nerve blocks, pudendal nerve block, sympathetic blocks, lumbar sympathetic blocks, ganglion impar block, superior hypogastric plexus block, nerve hydrodissection, spine injections, medication management, pain psychology, rehabilitation, or specialty coordination when appropriate.
Before a DRG stimulation trial, MPM reviews the diagnosis, pain pattern, prior treatments, imaging, medications, medical risks, psychological readiness, infection risk, insurance requirements, and treatment goals. Patients may need imaging review, medical clearance, psychological screening, medication review, and insurance authorization before proceeding.
During the trial, temporary leads are placed near the targeted dorsal root ganglion pathway and connected to an external device. The patient tracks pain relief, function, sleep, activity tolerance, stimulation comfort, and side effects. If the trial provides meaningful benefit and is well tolerated, permanent implantation may be discussed. If the trial does not help, the temporary leads are removed and permanent implantation is usually not recommended.
I cannot say enough good things about Manhattan Pain Medicine. From the moment I walked in, I felt truly cared for and taken seriously. Dr. Nino Mikaberidze, Director of Rheumatology, is exceptional — knowledgeable, compassionate, and incredibly thorough. She takes the time to listen, explains every...
The best care I've received as a chronic pain patient. I traveled from out of state to visit Manhattan Pain Medicine because I could not find knowledgeable doctors in my hometown for my hypermobility, and Ehlers-Danlos syndrome symptoms and comorbidities. Let me tell you, it was worth every travel e...
I was injured in a bicycle accident over 8 years ago. I’ve suffered throughout the years since my accident with nothing seeming to work. PT, Yoga, lifestyle changes, NOTHNG! I finally made an appointment with Dr Kane and I’m feeling an improvement in my life. I no longer stay up all night in pain, a...
One of the best experiences, if not the best, I have ever had at the doctor’s office. From the front desk to the nurses to the PA assisting the doctor this was a great experience. Dr.Nino actually listened to me and came up with a game plan. Would recommend this practice to as many people as I could...
I have very unique & severe nerve pain from CRPS which has no known specific cure. Dr. Siefferman has a huge tool box, far greater than the other 23 Drs. I have seen. He saved me from jumping off a bridge and continues to help me with both treatments and advice. Dr. S. is in a different league!
After two years of searching and feeling lost and let down, I finally found real help at Manhattan Pain Medicine. With Dr. Siefferman, Adam Rosenberg, Dr. Mikaberidze, and the whole team, I feel heard, supported and understood. Every symptom is being considered and I’m finally getting answers with m...
Why is Dr Dr. Tayyaba Ahmed one of the top pevic Floor specialists - 1- She wants to know a full history of what led the patient to get to this point. 2 - She listens intensley to the patient 3- She does not rush you 4- Extremely skilled at giving pelvic floor injections 5- I thank my luck stars she...
The staff was friendly and helpful. Dr. Siefferman was thoughtful, listened, asked questions and proposed simple safe ways to come to further conclusions regarding my pain and discomfort. The office staff including Dr. Siefferman is responsive even after the initial in-person visit. Very pleased.
Dr. Siefferman is a brilliant provider. While my pain is still a work in progress, Dr Siefferman always gives me options and explains his reasoning behind things. He listens to my feedback and concerns. I never feel rushed; and am grateful he works to meet me where I am. I highly recommend him.
What a great find! They listen to me, I listen to them and the diagnosis is made and a plan developed to develop an approach to treat all of my chronic pain. I wish I could have discovered this type of treatment sooner. This doctor and group give me hope.
Dorsal root ganglion stimulation is a neuromodulation treatment that uses targeted electrical stimulation near the dorsal root ganglion to help modulate pain signals from specific body regions. It may be considered for selected patients with focal nerve-related pain, CRPS, foot pain, groin pain, pelvic pain overlap, or complex chronic pain after other treatments have not provided enough relief.
DRG stimulation is another name for dorsal root ganglion stimulation. The dorsal root ganglion is a sensory nerve structure near the spine that helps transmit pain signals from specific regions of the body. DRG stimulation targets this area to help change how pain signals are processed. At MPM, DRG stimulation is considered only after diagnosis-first evaluation and usually begins with a temporary trial.
The dorsal root ganglion is a cluster of sensory nerve cells located near the spine. It helps transmit sensory information, including pain signals, from specific body regions toward the spinal cord and brain. Because the dorsal root ganglion is linked to defined pain territories, it may be a useful neuromodulation target for selected focal pain patterns.
DRG stimulation delivers controlled electrical stimulation near the dorsal root ganglion to help modulate pain signaling. It does not repair tissue, reverse nerve injury, cure CRPS, or eliminate every pain generator. The goal is to reduce pain signaling in a targeted pathway when the pain pattern and patient selection support this approach.
DRG stimulation may be considered for selected focal neuropathic pain, CRPS, lower extremity pain, foot pain, groin pain, pelvic pain overlap, pudendal neuralgia overlap, sciatica, spine-related nerve pain, or complex chronic pain. It is not appropriate for every chronic pain condition. MPM evaluates the diagnosis, pain distribution, prior treatment response, and safety factors before recommending a trial.
DRG stimulation may be considered for selected patients with CRPS, especially when the pain is regional or focal and has not improved enough with other treatments. It is not a cure for CRPS, and response varies. MPM evaluates pain distribution, autonomic features, functional goals, prior sympathetic block response, and whether DRG stimulation or another neuromodulation approach may be more appropriate.
DRG stimulation may be considered for selected foot, leg, or lower extremity nerve pain when symptoms follow a focal pattern that may correspond to a targetable nerve pathway. MPM evaluates whether symptoms are related to CRPS, nerve root irritation, peripheral nerve entrapment, spine disease, foot or ankle pathology, or another pain generator before considering DRG stimulation.
DRG stimulation may be considered for selected pelvic pain patterns when symptoms appear to involve focal nerve or neuromodulatory pathways. Pelvic pain can also come from pelvic floor dysfunction, pudendal neuralgia, endometriosis, pelvic dystonia, peripheral nerve pain, orthopedic contributors, or central sensitization. MPM evaluates these contributors before recommending a DRG stimulation pathway.
DRG stimulation may be considered in selected cases of pudendal neuralgia overlap, especially when symptoms are focal, persistent, and have not improved enough with other care. Some patients may be better suited for pudendal nerve block, nerve hydrodissection, peripheral nerve stimulation, pelvic floor therapy, or other treatments. MPM reviews pain mapping, block response, anatomy, and prior care before making a recommendation.
DRG stimulation may be considered for selected spine-related nerve pain or sciatica when symptoms persist despite appropriate treatment and the pain distribution is suitable for DRG targeting. MPM reviews imaging, nerve symptoms, prior epidural response, spine history, surgical history, and alternative pain generators before considering DRG stimulation.
Spinal cord stimulation targets broader spinal pain pathways, while DRG stimulation targets specific dorsal root ganglion structures involved in sensory and pain signaling from defined body regions. DRG stimulation may be more relevant for selected focal pain patterns. MPM compares both options based on the diagnosis, pain distribution, prior response, anatomy, and goals.
DRG stimulation targets a sensory nerve structure near the spine. Peripheral nerve stimulation targets a specific peripheral nerve farther from the spine. The best option depends on where the pain appears to originate, how focal the symptoms are, whether a peripheral nerve target is identifiable, and how the patient responded to prior diagnostic treatments.
A DRG stimulation trial is a temporary test period before permanent implantation. Temporary leads are placed near the targeted dorsal root ganglion pathway and connected to an external device. The patient tracks pain relief, function, sleep, activity tolerance, stimulation comfort, and side effects. The trial helps determine whether permanent implantation should be considered.
If the DRG stimulation trial provides meaningful improvement in pain or function and the stimulation is well tolerated, permanent implantation may be discussed. MPM reviews the trial response, patient goals, risks, insurance requirements, and long-term device responsibilities before moving forward. A successful trial does not guarantee permanent results, but it provides important decision-making information.
If the trial does not provide meaningful relief or is not tolerated, the temporary leads are removed and permanent implantation is usually not recommended. A failed trial does not mean the pain is not real. It may mean that the pain pathway is not appropriate for DRG stimulation or that another treatment, such as spinal cord stimulation, peripheral nerve stimulation, medication management, injections, surgery, or rehabilitation, may need to be considered.
Risks may include pain flare, infection, bleeding, lead migration, lead fracture, device malfunction, uncomfortable stimulation, loss of benefit, implant site pain, need for reprogramming, battery replacement, revision surgery, nerve irritation, dural puncture headache, rare neurologic injury, and incomplete relief. MPM reviews risks, alternatives, and long-term device considerations before treatment.
DRG stimulation may not be appropriate when the pain generator is unclear, when pain is too widespread for focal targeting, when less invasive options have not been fully evaluated, when infection risk is high, when medical clearance is not adequate, when psychological readiness is not appropriate, or when symptoms are better explained by another condition requiring different care. MPM also screens for urgent symptoms before recommending a DRG pathway.
Before care begins, our team helps patients understand the practical side of treatment, including insurance verification, out-of-network benefits, cost-share estimates, self-pay options, and billing questions. We believe patients should have as much clarity as possible before moving forward.
If you are considering dorsal root ganglion stimulation in NYC for CRPS, focal nerve pain, foot pain, groin pain, pelvic pain, pudendal neuralgia overlap, sciatica, spine-related nerve pain, or complex chronic pain, MPM can help determine whether this treatment pathway may be appropriate. Your evaluation will consider your diagnosis, pain distribution, prior care, safety factors, treatment goals, and whether DRG stimulation, spinal cord stimulation, peripheral nerve stimulation, or another option may fit your care plan.
Dorsal root ganglion stimulation is an advanced neuromodulation treatment that targets the dorsal root ganglion, a cluster of sensory nerve cells near the spine involved in transmitting pain signals from specific body regions.
At Manhattan Pain Medicine (MPM), dorsal root ganglion stimulation NYC care begins with diagnosis-first evaluation. The goal is to determine whether the patient’s pain pattern is focal enough, anatomically appropriate, and clinically suitable for DRG stimulation before considering a temporary trial. DRG stimulation is not a cure for chronic pain, and it is not appropriate for every patient.
The dorsal root ganglion is part of the sensory nervous system. It helps carry signals from specific regions of the body toward the spinal cord and brain. Because each dorsal root ganglion is associated with certain sensory territories, it may be a useful target when pain is focal, regional, and nerve-related.
This is why DRG stimulation may be considered for selected patients with focal lower extremity pain, foot pain, groin pain, pelvic pain overlap, pudendal neuralgia overlap, CRPS, or other regional nerve pain patterns. The treatment is selected based on anatomy and pain distribution, not simply because a patient has chronic pain.
DRG stimulation delivers controlled electrical stimulation near the dorsal root ganglion to help modulate pain signaling. The goal is to reduce the intensity or impact of pain signals in a specific pathway.
DRG stimulation does not repair damaged tissue, cure CRPS, reverse spine disease, eliminate endometriosis, or correct every pain generator. For selected patients, it may help reduce pain, improve function, improve tolerance for activity, or support broader pain care goals. Results vary, which is why trialing is an important part of the decision-making process.
DRG stimulation may be considered for selected patients with CRPS, focal neuropathic pain, lower extremity nerve pain, foot pain, groin pain, pelvic pain overlap, pudendal neuralgia overlap, sciatica, spine-related nerve pain, central pain features, or complex chronic pain.
The key question is whether the pain distribution is focal enough and whether the suspected pain pathway can be meaningfully targeted. Widespread pain, unclear pain generators, active inflammatory disease, untreated structural problems, or pain primarily driven by another condition may require a different approach.
DRG stimulation has been studied most strongly in selected CRPS and causalgia-type pain patterns, particularly involving the lower extremity. It may be considered when symptoms remain severe or functionally limiting despite medication, physical therapy, injections, sympathetic blocks, pain psychology, or other treatments.
MPM evaluates the pain location, autonomic features, sensitivity, swelling, color or temperature changes, movement tolerance, prior sympathetic block response, and functional goals before considering DRG stimulation. For some patients, spinal cord stimulation or peripheral nerve stimulation may be more appropriate.
DRG stimulation may be especially relevant when pain is regional and difficult to capture with broader stimulation approaches. This can include selected cases of foot pain, groin pain, lower extremity neuropathic pain, pelvic pain overlap, or pudendal neuralgia overlap.
Pelvic and groin pain require especially careful evaluation because symptoms may come from pelvic nerves, pudendal neuralgia, endometriosis, pelvic floor dysfunction, spine-related nerve pain, peripheral nerve entrapment, orthopedic structures, or central sensitization. MPM uses pain mapping, prior block response, imaging review, and treatment history to determine whether DRG stimulation should be considered.
Some patients with persistent spine-related nerve pain, radicular pain, or sciatica may ask whether DRG stimulation is appropriate. The answer depends on the pain distribution, imaging findings, prior treatment response, and whether the symptoms are more consistent with a targetable nerve pathway or another pain generator.
MPM reviews whether epidural injections, spine injections, epidural lysis of adhesions, medication management, physical therapy, surgery referral, spinal cord stimulation, or DRG stimulation best fits the clinical picture.
DRG stimulation and spinal cord stimulation are both forms of neuromodulation, but they are not the same. Spinal cord stimulation targets broader spinal pain pathways. DRG stimulation targets specific dorsal root ganglion structures that may correspond to more focal body regions.
DRG stimulation may be considered when pain is more localized or regional. Spinal cord stimulation may be more appropriate for broader pain distributions. MPM compares both options based on diagnosis, anatomy, pain mapping, prior treatments, patient goals, and trial planning.
Peripheral nerve stimulation targets a specific peripheral nerve outside the spinal canal. DRG stimulation targets sensory nerve structures near the spine. Some focal pain patterns may be better suited for peripheral nerve stimulation if a clear peripheral nerve target is identified. Other patterns may be better suited for DRG stimulation if the pain distribution aligns more closely with a dorsal root ganglion pathway.
MPM evaluates prior nerve blocks, peripheral nerve mapping, pelvic nerve findings, spine findings, and response to prior procedures before recommending a pathway.
A DRG stimulation trial is typically performed before permanent implantation. Temporary leads are placed near the targeted dorsal root ganglion pathway and connected to an external device. The patient then evaluates pain relief, function, sleep, activity tolerance, stimulation comfort, and side effects.
A successful trial usually means the patient experiences meaningful improvement in pain or function with tolerable stimulation and acceptable safety. The exact threshold for success depends on the patient’s condition, goals, functional limitations, and clinical context. If the trial is successful, permanent implantation may be discussed. If the trial does not help, the temporary leads are removed and permanent implantation is usually not recommended.
DRG stimulation may require imaging review, psychological screening, medical clearance, medication review, infection risk assessment, insurance authorization, and long-term device follow-up.
Risks may include pain flare, infection, bleeding, lead migration, lead fracture, device malfunction, uncomfortable stimulation, loss of benefit, implant site pain, need for reprogramming, battery replacement, revision surgery, nerve irritation, dural puncture headache, rare neurologic injury, incomplete relief, or no relief.
Patients should seek urgent evaluation for fever, wound drainage, spreading redness, severe swelling, new weakness, new numbness, bowel or bladder dysfunction, saddle anesthesia, severe headache after a procedure, chest pain, shortness of breath, severe allergic reaction, rapidly worsening pain, device-related burning or shocking sensation, or new neurological symptoms.
For selected patients, DRG stimulation may be an important part of an advanced chronic pain plan. MPM’s role is to determine whether the pain pathway is appropriate, whether the patient is ready for a trial, and how DRG stimulation fits within a coordinated, diagnosis-first care plan.
